Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2024; 16(10): 1151-1157
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1151
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1151
Chronic hepatitis B: Prevent, diagnose, and treat before the point of no return
Sudheer Marrapu, Ramesh Kumar, Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, India
Author contributions: Marrapu S designed and wrote the manuscript; Kumar R wrote the manuscript and provided critical inputs. All authors have read and approved the final manuscript.
Conflict-of-interest statement: None of the authors have any conflict-of-interest related to this work.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ramesh Kumar, MBBS, MD, Additional Professor, Department of Gastroenterology, All India Institute of Medical Sciences, Phulwari Sharif, Patna 801507, India. docrameshkr@gmail.com
Received: July 27, 2024
Revised: September 26, 2024
Accepted: October 10, 2024
Published online: October 27, 2024
Processing time: 85 Days and 15.5 Hours
Revised: September 26, 2024
Accepted: October 10, 2024
Published online: October 27, 2024
Processing time: 85 Days and 15.5 Hours
Core Tip
Core Tip: Hepatitis B remains a significant global health challenge. Despite ongoing efforts by the World Health Organization to eliminate hepatitis B as a public health concern by 2030, the situation on the ground is dire, with only about 13% of those infected diagnosed and merely 2.6% receiving treatment. In sub-Saharan Africa, awareness of hepatitis B virus infection is alarmingly low (1%), and many cases are identified only at the stage of cirrhosis, when the benefits of therapy are significantly reduced. This editorial aim to elucidate the challenges and explore potential strategies to improve the quality of care for such patients.